U.S. Healthtech Stock News

NasdaqCM:KARO
NasdaqCM:KAROSoftware

Karooooo (NasdaqCM:KARO) Margin Compression Tests Bullish Earnings Narratives

Karooooo (NasdaqCM:KARO) has closed out FY 2026 with fourth quarter revenue of ZAR 1.4b and basic EPS of ZAR 7.19, set against trailing 12 month revenue of ZAR 5.5b and EPS of ZAR 32.17 that frame the full year earnings picture. Over recent periods, the company has seen quarterly revenue move from ZAR 1.2b in Q4 FY 2025 to ZAR 1.4b in Q4 FY 2026, with basic EPS across the same quarters at ZAR 8.11 and ZAR 7.19 respectively. Investors are likely to focus on how these results sit with a net...
NasdaqGS:DXCM
NasdaqGS:DXCMMedical Equipment

Is DexCom’s (DXCM) Governance Shake-Up Enough To Unlock Its Automated Insulin Ecosystem Potential?

Earlier this month, DexCom outlined governance changes ahead of its 2026 Investor Day, agreeing with Elliott Investment Management to recruit two new independent directors and expanding its Board Technology Committee into an Operations and Innovation Committee with broader oversight of operations, quality, and the technical roadmap. A separate announcement from ViCentra showed DexCom’s G7 continuous glucose monitor embedded in a new smartphone-controlled hybrid closed-loop insulin patch pump...
NasdaqGS:MORN
NasdaqGS:MORNCapital Markets

Is It Time To Reassess Morningstar (MORN) After A 46% One Year Share Price Slide

If you are wondering whether Morningstar stock now offers value after a rough patch, starting with a clear look at price versus fundamentals can help frame your next move. The stock closed at US$166.05, with the share price declining 6.7% over the past week, 3.6% over the past month, 21.1% year to date, and 46.0% over the past year, which can change how investors think about both risk and opportunity. Recent coverage has focused on how market sentiment toward Morningstar has shifted, as...
NasdaqCM:VKTX
NasdaqCM:VKTXBiotechs

How New Oral VK2735 Obesity Data At Viking Therapeutics (VKTX) Has Changed Its Investment Story

Viking Therapeutics recently presented additional Phase 2 VENTURE-Oral trial data for its oral VK2735 obesity therapy at the European Congress on Obesity 2026 in Istanbul, highlighting statistically significant, dose-dependent weight loss over 13 weeks with a generally mild to moderate side-effect profile. The absence of a weight-loss plateau at higher VK2735 doses and the high proportion of patients reaching at least 5% and 10% weight loss underscore how this oral dual GLP-1/GIP agonist...
NYSE:SAM
NYSE:SAMBeverage

Has Boston Beer Company (SAM) Share Price Slide Created A Potential Opportunity For Investors

If you are wondering whether Boston Beer Company stock now offers value or just more volatility, the recent share price moves give you plenty to think about. The stock is currently at US$173.18, with the share price down 14.7% over the past week, down 26.7% over the past month, and down 13.3% year to date. This may signal changing views on its potential and risk. Over a longer horizon, the share price has fallen 29.5% over the past year, 46.9% over three years and 83.5% over five years. This...
NYSE:BKV
NYSE:BKVOil and Gas

How BKV’s Q1 2026 Earnings Rebound and Output Surge Will Impact BKV (BKV) Investors

BKV Corporation recently reported past first-quarter 2026 results, with sales of US$71.29 million, revenue of US$432.85 million and net income of US$44.08 million, alongside higher production of 83,253 MMcfe versus 68,503 MMcfe a year earlier. The shift from a net loss and loss per share a year ago to positive earnings, combined with new production guidance of 925–975 MMcfe/d for the second quarter of 2026, highlights a sharp improvement in operating performance and management’s confidence...
NasdaqGS:TENB
NasdaqGS:TENBSoftware

Tenable Awards Key Partners As Tenable One Ecosystem Shapes Growth Story

Tenable Holdings honored its top global partners at the AssureWorld conference, recognizing Deloitte, Atos, and eSentire. The awards highlight partner contributions to expanding the Tenable One Exposure Management Platform. The event focused on advancing preemptive security adoption across Tenable's global customer base. Tenable Holdings (NasdaqGS:TENB) is putting its partner ecosystem front and center, using this year's AssureWorld conference to spotlight firms that are helping scale the...
NYSEAM:BKTI
NYSEAM:BKTICommunications

BK Technologies (BKTI) Margin Expansion To 16% Tests Slower Growth Narrative

BK Technologies (BKTI) has put fresh numbers on the board for Q1 2026, reporting revenue of US$21.3 million and basic EPS of US$0.74, supported by trailing 12 month revenue of US$88.4 million and basic EPS of US$3.81. Over the past year, the company has seen revenue move from US$76.6 million to US$88.4 million and basic EPS lift from US$2.35 to US$3.81 on a trailing 12 month basis, while net profit margin has improved to 16% from 12.7%. This sets up a story in which investors may focus on how...
NasdaqGS:DLO
NasdaqGS:DLODiversified Financial

A Look At DLocal (DLO) Valuation After Mixed Q1 2026 Revenue And Earnings Results

DLocal (DLO) shares are in focus after the company reported first quarter 2026 results, with sales of US$335.86 million and net income of US$41.98 million, along with lower earnings per share year over year. See our latest analysis for DLocal. At a share price of US$12.66, DLocal has seen a 1-day share price return of 4.03%, while the year-to-date share price return has declined 10.02%. However, the 1-year total shareholder return is 17.98%, suggesting recent momentum has cooled after...
NasdaqGM:AQST
NasdaqGM:AQSTPharmaceuticals

Aquestive Therapeutics (AQST) Q1 Loss Per Share Narrows Challenging Bearish Narratives

Aquestive Therapeutics (AQST) opened Q1 2026 with revenue of US$14.4 million and a reported loss of US$8.1 million, equal to a basic EPS loss of US$0.07. The trailing twelve months show revenue of US$50.3 million and a net loss of US$68.9 million or EPS of US$0.61. Over recent quarters the company has reported revenue rising from US$8.7 million in Q1 2025 to US$14.4 million in Q1 2026, with quarterly EPS losses ranging from US$0.24 to US$0.26 through 2025 before narrowing to US$0.07 in the...
NYSE:CRC
NYSE:CRCOil and Gas

How CRC’s Dividend, Losses and Carbon Capture Push Will Impact California Resources (CRC) Investors

In the first quarter of 2026, California Resources Corporation reported revenue of US$119 million versus US$912 million a year earlier, swinging from net income of US$115 million to a net loss of US$711 million, yet its board still declared a quarterly dividend of US$0.405 per share payable in June. Despite the sharp year-on-year earnings deterioration, the company raised full-year 2026 production guidance and highlighted progress on its carbon capture and storage project at the Elk Hills...
NYSE:EL
NYSE:ELPersonal Products

Estée Lauder UK Lawsuit Puts Governance And Puig Deal In Focus

Estée Lauder Companies (NYSE:EL) is facing new UK litigation tied to its Jo Malone business. The case includes allegations of insider trading and fiduciary breaches involving senior executives. The legal action is emerging while the company is engaged in public merger negotiations with Puig. For investors watching NYSE:EL, these governance allegations arrive at a sensitive time. The stock last closed at $80.83, with shares down 24.3% year to date and 57.3% over three years, while still up...
NasdaqGM:CRMD
NasdaqGM:CRMDPharmaceuticals

CorMedix (CRMD) Q1 Earnings Margin Surge Tests Bearish Narratives

CorMedix (CRMD) has opened 2026 with Q1 revenue of US$127.4 million and basic EPS of US$0.49, set against a very large year over year earnings expansion and a move in net profit margin from 20.8% to 45% over the past 12 months. The company has seen quarterly revenue step up from US$39.1 million in Q1 2025 to US$127.4 million in Q1 2026. Trailing twelve month EPS has moved from US$0.28 at the start of 2025 to US$2.38 by Q1 2026. This gives investors a results set where wider margins and higher...
NYSE:KVUE
NYSE:KVUEPersonal Products

Assessing Kenvue (KVUE) Valuation After Recent Share Weakness And Mixed Earnings Multiple Signals

Kenvue (KVUE) has drawn investor attention after recent share performance data showed the stock flat over 1 day, down about 3% over the past week, and weaker over the past year. See our latest analysis for Kenvue. At a share price of US$17.19, Kenvue’s recent 7 day and 90 day share price returns, which declined 2.99% and 8.07% respectively, line up with a weaker 1 year total shareholder return that fell 24.68%. This suggests fading momentum as investors reassess its risk and return...
NasdaqGM:ENPH
NasdaqGM:ENPHSemiconductor

Has The Recent Rebound Left Enphase Energy (ENPH) Trading Ahead Of Its Fundamentals

Wondering whether Enphase Energy's share price reflects its true worth, or if the recent moves have left it mispriced. The stock closed at US$48.01 after a sharp rebound, with returns of 35.4% over the past week, 50.0% over the past month and 42.3% year to date, even though the 1 year, 3 year and 5 year returns are down 3.4%, 70.7% and 66.1% respectively. Recent coverage has focused on how Enphase Energy fits into the broader semiconductor and clean energy story, with investors reacting to...
NYSE:BLK
NYSE:BLKCapital Markets

Is It Too Late To Consider BlackRock (BLK) After Strong Multi‑Year Share Gains?

For investors wondering whether BlackRock, at around US$1,104 per share, represents value or simply a premium price tag, this article outlines what the current data can and cannot indicate about that question. The stock has delivered returns of 3.4% over the past week, 4.7% over the past month, 1.7% year to date and 14.6% over the past year, with 3 year and 5 year returns of 77.0% and 47.3% respectively. These figures naturally raise questions about how much potential future upside or...
NYSE:GNL
NYSE:GNLREITs

Is Global Net Lease (GNL) Offering Value After A 26% One Year Share Price Rise

Wondering whether Global Net Lease at about US$9.20 is offering fair value or an opportunity? This article walks through what the current price may be implying. The stock is up 0.9% over the last week, has slipped 3.1% over the last month, yet sits 4.3% higher year to date and 26.3% higher over the past year. These moves can change how you think about both upside and risk. Recent headlines have focused on Global Net Lease as part of broader discussions around US listed real estate investment...
NasdaqGS:SIMO
NasdaqGS:SIMOSemiconductor

Silicon Motion Technology (SIMO) Is Up 8.7% After Record Q1 Results And Confident Q2 Outlook - Has The Bull Case Changed?

In early May 2026, Silicon Motion Technology reported record Q1 2026 revenue of US$342.1 million, a gross margin of 47.2%, and earnings per share of US$1.58, alongside management guidance for further sequential growth in Q2 driven by datacenter demand, mobile market share gains, and the MonTitan product ramp-up. The combination of strong quarterly execution and management’s confidence in near-term demand drivers has reinforced Silicon Motion’s positioning in higher-performance storage...
NasdaqGM:FATE
NasdaqGM:FATEBiotechs

Fate Therapeutics (FATE) Q1 Losses Reinforce Concerns Over Rich 35.1x P/S Valuation

Fate Therapeutics (FATE) opened 2026 with Q1 results showing revenue of about US$1.3 million and a basic EPS loss of US$0.26, alongside a net loss of US$31.2 million. Over recent quarters the company has seen quarterly revenue sit in a tight band around US$1.3 million to US$1.9 million, while basic EPS losses have moved between roughly US$0.26 and US$0.44 and trailing twelve month EPS has been around a US$1.09 loss. With the stock trading near US$1.90, the key question for investors is...
NYSE:AVA
NYSE:AVAIntegrated Utilities

Assessing Avista (AVA) Valuation As New Microgrid Project Highlights Its Energy Resilience Focus

Avista (AVA) is drawing fresh attention after Avista Utilities started operating a community-based microgrid at Spokane’s Dr. Martin Luther King Jr. Family Outreach Center. The project combines solar, battery storage, and natural gas to support energy resilience. See our latest analysis for Avista. At a share price of $41.16, Avista has delivered a 6.30% year to date share price return, while the 1 year total shareholder return of 11.34% suggests interest has been building around its recent...
NasdaqGS:ENVX
NasdaqGS:ENVXElectrical

Enovix (ENVX) TTM Loss Of US$171 Million Tests Bullish Growth Narratives

Enovix (ENVX) opened Q1 2026 with revenue of US$7.6 million and a basic EPS loss of US$0.18, alongside a net loss of US$38.26 million. On a trailing 12 month basis, the company generated US$34.32 million of revenue and a basic EPS loss of US$0.81 tied to a US$171.49 million net loss. Over recent quarters, the company has seen revenue range from US$5.10 million to US$11.27 million with quarterly basic EPS losses between US$0.12 and US$0.26. This provides a clear view of how growth and losses...
NasdaqGS:AKAM
NasdaqGS:AKAMIT

Akamai LayerX Acquisition Puts AI Browser Security And Valuation In Focus

Akamai Technologies (NasdaqGS:AKAM) has agreed to acquire LayerX, a provider of browser-based AI usage control and secure enterprise browser technology. The deal extends Akamai’s Zero Trust portfolio into browser-level protection for generative AI applications used inside enterprises. The acquisition targets growing enterprise concerns around how employees access and use AI tools through their web browsers. Akamai Technologies, trading at $155.67, has seen strong recent share price...
NYSE:SMWB
NYSE:SMWBSoftware

Similarweb (SMWB) Q1 Loss Narrows And Tests Bearish Profitability Narratives

Similarweb Q1 2026: Revenue Edges Higher While Losses Persist Similarweb (SMWB) opened 2026 with Q1 revenue of US$73.9 million and a basic EPS loss of US$0.07, while trailing 12 month revenue sat at US$289.4 million and EPS at a loss of US$0.35. The company has seen quarterly revenue move from US$67.1 million in Q1 2025 to US$73.9 million in Q1 2026, with basic EPS losses over that span ranging between US$0.05 and US$0.14 per quarter as management works toward narrowing the gap between top...
OTCPK:FCCN
OTCPK:FCCNIT

Spectral Capital (OTCPK:FCCN) Q1 Loss Deepens To US$0.11 EPS Challenging Profitability Narratives

Spectral Capital (OTCPK:FCCN) has just posted Q1 2026 revenue of roughly US$328.5 million, alongside a basic EPS loss of US$0.11 and a net loss of about US$9.4 million, setting a clear tone for the quarter. The company has seen revenue move from US$0 in Q1 2025 to US$328.5 million in Q1 2026, while basic EPS has shifted from a loss of US$0.01 to a deeper loss of US$0.11, indicating that margins are under pressure even as the top line scales rapidly. See our full analysis for Spectral...